‘Digital twins’ project will help clean up space junk, repair and decommission spacecrafts – University of California

Imagine Earth from space: a blue marble, a pristine orb that is our one and only home. But like many other places on the planet itself, this view is littered with the evidence of humans: in the earths orbit floats more than 30,000 individual pieces of space debris larger than 10 cm, according to a 2023 report from the European Space Agency.

A new project led by Ricardo Sanfelice, UC Santa Cruz Professor and Department Chair of Electrical and Computer Engineering, will develop technology for better spacecraft that use complex robotics to clean up space debris, as well as repair, refuel and decommission other spacecraft. A research team will create highly detailed digital twin models of spacecraft that can carry out these complex tasks in space and develop next-generation control algorithms to manipulate those models, enabling experimentation without the costs of testing on the physical system.

Sanfelice and his research team have been awarded $2.5 million from the Air Force Office of Scientific Research (AFOSR) Space University Research Initiative (SURI) for this three-year project. Co-principal investigators include UC Santa Cruz Professor of Applied Mathematics Daniele Venturi, UT Austin Professor of Aerospace Engineering Karen Wilcox, and University of Michigan Professor of Aerospace Engineering Ilya Kolmanovsk; and the team will collaborate with government and industry partners including the Air Force Research Lab Space Vehicles Directorate, The University of Arizona, Raytheon Technologies, Trusted Space, Inc., and Orbital Outpost X.

A digital twin is a computer model of a physical system, designed to perfectly mimic the properties of the real-world object, including all of the instruments, computers, sensors, surrounding environment, and anything else the system might include. Digital twins enable researchers to conduct experiments and run analysis in the digital world, testing what concepts might work in the real world to determine if they are worth building and manufacturing.

Unlike more traditional simulations, digital twins often incorporate machine learning that allows the system to improve itself through experimentations, providing valuable iteration to build a more accurate and detailed system.

Digital twins can be useful in a range of engineering disciplines, but are particularly relevant for aerospace engineering where the costs associated with building the real systems are so high.

You can accelerate your production, you can reduce time and costs and risk of spacecraft design because spacecraft technology is very expensive and requires a lot of certification and regulation before they can go into space, Sanfelice said. Rather than performing those experiments which take a lot of time in the real world, with a digital twin you can do conceptual analysis and initial validation in the computer environment. This same logic extends to other complex and costly systems its all about scale and reduction of production time, cost, and risk while maintaining system performance and safety.

Digital twins are also especially useful for aerospace engineering because they allow engineers to test complex scenarios and so-called corner cases, situations where multiple parameters are at their extreme, within the realm of the computer. Highly complex and extreme situations are more likely to occur in the harsh conditions of space, and cant be fully replicated for experimentation back on Earth.

The models will enable the researchers to deeply examine what is necessary to carry out the highly complex tasks of clearing up space debris and using a spacecraft to refuel, repair, or demission other spacecraft. Such tasks could include a situation where a robotic arm on one spacecraft is trained to grab another spacecraft that is malfunctioning and tumbling through space, potentially damaging one or both of the systems. The researchers need to teach the computers to handle the tumbling and steering, developing optimization-based techniques to quickly compute and solve unexpected problems as they arise while also allowing for possible human intervention.

Sanfelice and his Hybrid Systems Lab will focus on developing the control algorithms that allow for experimentation on the spacecraft digital twins. The digital twin models need to be so complex to fully encapsulate the physics and computing variables of the real-world systems they represent, and this in turn requires new methods to control the models that go beyond the current state-of-the-art.

I have this massive detailed model of my system, it keeps updating as the system evolves and I run experiments can I write an algorithm that makes the digital twin do what I want it to do, and as a consequence hopefully the real physical system will do the same? Sanfelice said.

Sanfelices work will center around developing model predictive control algorithms, a type of optimization-based control scheme, to control the digital twins, of which Wilcox will lead the creation. Sanfelices lab develops robotic manipulators for grasping and other tasks performed by robotics, which require hybrid control schemes to enable the robotic fingers to be able to transition between conditions of contact and no contact with the object they are manipulating.

While the model predictive control techniques they develop for this project will be highly relevant to aerospace applications, Sanfelice believes there is an opportunity to expand to other complex application areas and develop more advanced basic science for digital twins and their control.

Continue reading here:

'Digital twins' project will help clean up space junk, repair and decommission spacecrafts - University of California

PHOTO OF THE DAY: NASA’s Hubble Telescope Captures Spiral Galaxy’s Dazzling Swirls – SpaceCoastDaily.com

one of 19 nearby spiral galaxies recently imaged by the telescope NGC 4254, a spiral galaxy, is resplendent in orange and blue in this Jan. 29, 2024, image from the James Webb Space Telescope. (NASA image)

(NASA) NGC 4254, a spiral galaxy, is resplendent in orange and blue in this Jan. 29, 2024, image from the James Webb Space Telescope.

This is one of 19 nearby spiral galaxies recently imaged by the telescope as part of the long-standing Physics at High Angular Resolution in Nearby GalaxieS program supported by more than 150 astronomers worldwide.

Webbs Near-Infrared Camera captured millions of stars in these images, which sparkle in blue tones. At the same time, the telescopes Mid-Infrared Instrument data highlights glowing dust, showing us where it exists around and between stars.

Explore the intricacies of spiral galaxies in this deep dive.

CLICK HERE FOR BREVARD COUNTY NEWS

Go here to read the rest:

PHOTO OF THE DAY: NASA's Hubble Telescope Captures Spiral Galaxy's Dazzling Swirls - SpaceCoastDaily.com

JPM2024: Big Tech Poised to Disrupt Biopharma with AI-Based Drug Discovery – BioSpace

Pictured: Medical professionals use technology in healthcare/iStock,elenabs

2024 will continue to see Big Tech companies enter the artificial intelligence-based drug discovery space, potentially disrupting the biopharma industry. That was the consensus of panelists at a Tuesday session on AI and machine learning held by the Biotech Showcase, co-located with the 42nd J.P. Morgan Healthcare Conference.

The JPM conference got a reminder of Big Techs inroads into AI-based drug discovery with Sundays announcement that Google parent Alphabets digital biotech company Isomorphic Labs signed two large deals worth nearly $3 billion with Eli Lilly and Novartis.

Big Tech is coming for AI and its coming in a big way, said panel moderator Beth Rogozinski, CEO of Oncoustics, who noted that the AI boom has seen the rise of the Magnificent 7, a new grouping of mega-cap tech stocks comprised of the seven largest U.S.-listed companiestech giants Amazon, Apple, Alphabet, Microsoft, Meta Platforms, Nvidia and Tesla.

Last year, the Magnificent 7s combined market value surged almost 75% to a whopping $12 trillion, demonstrating their collective financial power.

Six of the seven have AI and healthcare initiatives, Rogozinski told the panel. Theyre all coming for this industry.

However, Atomwise CEO Abraham Heifets made the case that with Big Tech getting into biopharma there is a mismatch of business models, with the Isomorphic Labs deals looking, in his words, like traditional tech mentality. Heifets contends that its unclear whether the physics of the business will support the risk models in the industry, adding that the influence of small- to mid-size companies focused on AI-based drug discovery should not be underestimated.

Google DeepMinds AlphaFold is the foundation of Isomorphic Labs platform. The problem, according to ArrePath CTO Kurt Thorn, is that its easy for these technologies to have fast followings only to see their market shares wane over time. If you look at AlphaFold, which was a breakthrough when it came out, within two or three years afterwards there were two or three alternatives.

Thorn concluded that its not clear that the market sizes are large enough to amortize a large AI platform for drug discovery across an entire industry.

Rogozinski emphasized that these switching costs are a potential barrier to entry in moving to such drug discovery platforms as Big Tech tries to get companies to transition.

Vivodyne CEO Andrei Georgescu commented that drug discovery and development is a difficult and complex process that is not a function of how big your team is or how many people you have behind the bench. The key to the success of AI in biopharma is in the generation and curation of datasets, according to Georgescu, who said the industry is facing a bottleneck on the complexity of the data and the applicability of the data to the outcomes that we want to confirm.

Providing some levity and perspective to Tuesdays AI session, Moonwalk Biosciences CEO Alex Aravanis told the audience he was late to arrive as a panelist due to an accident on the freeway involving a Tesla self-driving vehicle. So, clearly, they need more data, Aravanis said.

Marc Cikes, managing director of the Debiopharm Innovation Fund, told BioSpace that while he has been heartened to see the rise of AI and machine learning usage in biopharma, the forecast remains murky in 2024.

The impact of AI for drug discovery is still largely unknown, Cikes said. The public market valuation of the few AI-drug discovery companies is significantly down versus their peak price, and a large chunk of the high-value deals announced between native AI companies and large pharmas are essentially based on future milestone payments which may never materialize.

Greg Slabodkin is the News Editor at BioSpace. You can reach him atgreg.slabodkin@biospace.com. Follow him onLinkedIn.

See the original post here:

JPM2024: Big Tech Poised to Disrupt Biopharma with AI-Based Drug Discovery - BioSpace

Transhumanism: Integrating Cochlear Implants With Artificial Intelligence and the Brain-Machine Interface – Cureus

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

View post:

Transhumanism: Integrating Cochlear Implants With Artificial Intelligence and the Brain-Machine Interface - Cureus

Prostate Cancer in the Caribbean | Article – Cureus

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Excerpt from:

Prostate Cancer in the Caribbean | Article - Cureus